Regulation & law · 01/10/2020

National Cancer Institute to Grant Exclusive Patent License to Senti Biosciences for Allogeneic Therapy Using Armored Payload and Chimeric Antigen Receptors Targeting GPC3

The National Cancer Institute, part of the National Institutes of Health, Department of Health and Human Services, is considering granting an exclusive patent license to Senti Biosciences, a biotechnology company based in South San Francisco, California, for the use of its allogeneic therapy approach targeting GPC3.